Sinew Pharma Inc.

Sinew Pharma Inc. is a biopharmaceutical company focused on the research, development, and sale of drugs for hepatotoxicity-free acetaminophen and fatty liver diseases. Its products include SNP-610, in Phase IIa clinical trials, and SNP-630, in Phase II clinical trials for non-alcoholic steatohepatitis in Taiwan. The company is also developing SNP-810 for pain relief and fever reduction, SNP-820 as an antidote for acetaminophen poisoning, and SNP-830 and SNP-840 as hepatotoxicity-free analgesic medicines in the United States. Founded in 2014, Sinew Pharma Inc. is based in Taipei City, Taiwan.